Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Pancreatic Neoplasms 205Carcinoma, Non-Small-Cell Lung 130Neoplasms 101Neoplasm Metastasis 70Breast Neoplasms 66Ovarian Neoplasms 42Urinary Bladder Neoplasms 37Lung Neoplasms 37Triple Negative Breast Neoplasms 34Colorectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 29Cholangiocarcinoma 28Biliary Tract Neoplasms 27Carcinoma, Transitional Cell 23Lymphoma, Non-Hodgkin 22Adenocarcinoma 22Recurrence 21Lymphoma 20Fallopian Tube Neoplasms 18Stomach Neoplasms 15Sarcoma 15Parkinson Disease 4, Autosomal Dominant Lewy Body 15Non-Muscle Invasive Bladder Neoplasms 13Carcinoma, Pancreatic Ductal 13Nasopharyngeal Carcinoma 12Gallbladder Neoplasms 12Bile Duct Neoplasms 11Melanoma 10Carcinoma 10Solid Tumors 9

Interventions

Temozolomide 4Irinotecan 4eribulin 2Topotecan 2LY2940680 2technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1surufatinib 1sonidegib 1soblidotin 1ribociclib 1regorafenib 1pegfilgrastim 1palbociclib 1omburtamab I-131 1lenvatinib 1iso-sulfan blue 1dostarlimab 1dinutuximab 1copanlisib 1cixutumumab 1ceritinib 1bempegaldesleukin 1amino-acid, glucose, and electrolyte solution 1abemaciclib 1Vincristine 1Pemetrexed 1Nivolumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Rhabdomyosarcoma × Gemcitabine × Clear all
NCT05093322 2024-06-07

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Hutchmed

Phase 1/2 Completed
13 enrolled 17 charts
LymphoidSarcoma

Lymphoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡